vs
Ellington Financial Inc.（EFC）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
Ellington Financial Inc.的季度营收约是RIGEL PHARMACEUTICALS INC的1.1倍（$78.2M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 28.9%，领先355.1%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs 8.7%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 1.8%）
埃林顿金融是一家美国对冲基金机构，专注于结构化产品及其他信贷工具领域的投资管理。截至2019年6月，公司公开披露的管理资产规模达85亿美元，在另类投资和信用资管领域拥有成熟的运营经验。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
EFC vs RIGL — 直观对比
营收规模更大
EFC
是对方的1.1倍
$69.8M
营收增速更快
RIGL
高出12.5%
8.7%
净利率更高
RIGL
高出355.1%
28.9%
两年增速更快
RIGL
近两年复合增速
1.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $78.2M | $69.8M |
| 净利润 | $22.6M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | 7.4% | 33.2% |
| 净利率 | 28.9% | 384.0% |
| 营收同比 | 8.7% | 21.2% |
| 净利润同比 | -26.2% | 1769.2% |
| 每股收益（稀释后） | $0.10 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EFCRIGL
| Q4 25 | $78.2M | $69.8M | ||
| Q3 25 | $82.8M | $69.5M | ||
| Q2 25 | $92.5M | $101.7M | ||
| Q1 25 | $82.9M | $53.3M | ||
| Q4 24 | $72.0M | $57.6M | ||
| Q3 24 | $67.0M | $55.3M | ||
| Q2 24 | $91.2M | $36.8M | ||
| Q1 24 | $75.5M | $29.5M |
净利润EFCRIGL
| Q4 25 | $22.6M | $268.1M | ||
| Q3 25 | $29.5M | $27.9M | ||
| Q2 25 | $42.9M | $59.6M | ||
| Q1 25 | $31.6M | $11.4M | ||
| Q4 24 | $30.7M | $14.3M | ||
| Q3 24 | $16.2M | $12.4M | ||
| Q2 24 | $52.3M | $-1.0M | ||
| Q1 24 | $26.9M | $-8.2M |
毛利率EFCRIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率EFCRIGL
| Q4 25 | 7.4% | 33.2% | ||
| Q3 25 | 31.1% | 40.9% | ||
| Q2 25 | 38.3% | 60.1% | ||
| Q1 25 | 37.3% | 23.9% | ||
| Q4 24 | 28.0% | 28.9% | ||
| Q3 24 | 24.0% | 25.4% | ||
| Q2 24 | 52.8% | 1.2% | ||
| Q1 24 | 42.2% | -23.6% |
净利率EFCRIGL
| Q4 25 | 28.9% | 384.0% | ||
| Q3 25 | 35.7% | 40.2% | ||
| Q2 25 | 46.4% | 58.6% | ||
| Q1 25 | 38.2% | 21.5% | ||
| Q4 24 | 42.6% | 24.9% | ||
| Q3 24 | 24.1% | 22.5% | ||
| Q2 24 | 57.4% | -2.8% | ||
| Q1 24 | 35.6% | -27.9% |
每股收益（稀释后）EFCRIGL
| Q4 25 | $0.10 | $14.11 | ||
| Q3 25 | $0.29 | $1.46 | ||
| Q2 25 | $0.45 | $3.28 | ||
| Q1 25 | $0.35 | $0.63 | ||
| Q4 24 | $0.23 | $0.82 | ||
| Q3 24 | $0.19 | $0.70 | ||
| Q2 24 | $0.62 | $-0.06 | ||
| Q1 24 | $0.32 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $201.9M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $1.8B | $391.5M |
| 总资产 | $19.4B | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资EFCRIGL
| Q4 25 | $201.9M | $155.0M | ||
| Q3 25 | $184.8M | $137.1M | ||
| Q2 25 | $211.0M | $108.4M | ||
| Q1 25 | $203.3M | $77.1M | ||
| Q4 24 | $192.4M | $77.3M | ||
| Q3 24 | $217.7M | $61.1M | ||
| Q2 24 | $198.5M | $49.1M | ||
| Q1 24 | $187.5M | $49.5M |
总债务EFCRIGL
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益EFCRIGL
| Q4 25 | $1.8B | $391.5M | ||
| Q3 25 | $1.8B | $117.6M | ||
| Q2 25 | $1.7B | $81.9M | ||
| Q1 25 | $1.6B | $18.6M | ||
| Q4 24 | $1.6B | $3.3M | ||
| Q3 24 | $1.6B | $-14.6M | ||
| Q2 24 | $1.6B | $-29.9M | ||
| Q1 24 | $1.5B | $-31.7M |
总资产EFCRIGL
| Q4 25 | $19.4B | $513.6M | ||
| Q3 25 | $17.8B | $242.5M | ||
| Q2 25 | $17.1B | $206.7M | ||
| Q1 25 | $16.6B | $176.0M | ||
| Q4 24 | $16.3B | $164.0M | ||
| Q3 24 | $16.0B | $139.4M | ||
| Q2 24 | $15.1B | $128.4M | ||
| Q1 24 | $15.1B | $126.5M |
负债/权益比EFCRIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-925.5M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | -40.92× | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流EFCRIGL
| Q4 25 | $-925.5M | $22.0M | ||
| Q3 25 | $-290.4M | $24.0M | ||
| Q2 25 | $-210.5M | $30.5M | ||
| Q1 25 | $-126.4M | $-893.0K | ||
| Q4 24 | $-430.5M | $14.5M | ||
| Q3 24 | $-141.7M | $21.7M | ||
| Q2 24 | $-88.6M | $302.0K | ||
| Q1 24 | $-59.5M | $-5.0M |
资本支出强度EFCRIGL
| Q4 25 | 0.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
现金转化率EFCRIGL
| Q4 25 | -40.92× | 0.08× | ||
| Q3 25 | -9.84× | 0.86× | ||
| Q2 25 | -4.90× | 0.51× | ||
| Q1 25 | -3.99× | -0.08× | ||
| Q4 24 | -14.04× | 1.01× | ||
| Q3 24 | -8.76× | 1.75× | ||
| Q2 24 | -1.69× | — | ||
| Q1 24 | -2.21× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
